Correction: mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company

View correction statement:

mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company

This article refers to:

mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company

The original article can be found online at https://doi.org/10.1186/s40545-023-00652-y.

Correction : Journal of Pharmaceutical Policy and Practice (2023) 16:158 https://doi.org/10.1186/s40545-023-00652-y

Following publication of the original article [1], it was reported that there were two incorrect references to “liquid nitrogen” in the ‘Supply and logistics’ section. These two instances have been replaced with “dry ice” as follows (correction in bold):

• This was achieved by shipping the vaccine vials in trays secured within thermal containers cooled with dry ice. This unusual requirement necessitated training of physicians and pharmacists in the safe handling of dry ice and the support of the Swiss military pharmacy for logistics and distribution.

The original article has been updated.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.